BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...

LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company advancing Lerodalcibep (LeroChol®), a novel, monthly, small dose third-generation PCSK9 inhibitor today announced ...

Certain potential users of Owkin K may be subject to anti-gift or anti-bribery regulations based on ... a First-in-Human Clinical Trial of an mRNA destabilizing drug targeting c-MYC driven cancers UTR ...

This disruption fosters the upregulation of oncogenic regulators such as c-Myc and Cyclin D1 ... of RA with cisplatin demonstrated synergistic anti-tumor efficacy, leading to greater reductions ...

Colorectal cancer is the third most diagnosed type of cancer worldwide. Up to 80% of the cases are related to environmental ...

and c-Myc, together known as OSKM factors. 3 This process not only resets cellular identity but also reverses age-associated epigenetic markers. The key mechanisms involved in reprogramming ...

were detected by immunofluorescence staining with anti-Flag or anti-Myc abs, respectively. Nucleus were stained by DAPI, Bar = 10 μm. (C) The lysates of HEK293T cells transfected with indicated ...